In Vivo Liver-Targeted
RNA Transfection Kit
Satreda LNP8002
A Versatile Platform for Systemic RNA Delivery
The SatredaLNP™ 8002 is a next-generation solution designed for broad, systemic RNA delivery across multiple tissues and organs. Developed using Satreda’s advanced in vivo LNP technology, LNP8002 integrates precision lipid engineering, optimized formulation chemistry, and customizable targeting ligand design to enable efficient, flexible, and safe RNA transfection in vivo. This kit represents a major leap forward for researchers and pharmaceutical developers seeking to advance RNA-based therapeutics, vaccines, and gene regulation studies.
Efficient, Ready-to-Use RNA Delivery Technology
At the heart of LNP8002 lies Satreda’s ready-to-use LNP encapsulation system, capable of completing RNA encapsulation in just one minute — dramatically faster than the traditional 10-hour or multi-day encapsulation methods. This innovation streamlines workflows while ensuring highly reproducible, stable LNP-RNA complexes for consistent in vivo performance. The system is entirely ethanol-free, eliminating potential irritation, hemolysis, or neurotoxicity while maintaining excellent biocompatibility and stability.
Broad RNA Compatibility for Multi-Functional Applications
LNP8002 supports a wide range of RNA types — including siRNA, miRNA, sgRNA, mRNA, and circRNA — allowing researchers to pursue diverse applications such as:
mRNA vaccines for infectious diseases or cancer immunotherapy.
siRNA- or miRNA-mediated gene silencing for target validation or therapeutic modulation.
CRISPR-based gene editing, delivering Cas9 mRNA and sgRNA for precise genome modification.
Protein replacement and functional rescue studies for metabolic or genetic disorders.
This versatility makes LNP8002 a universal platform for systemic RNA studies in both preclinical and translational research.
Passive Liver Targeting with Natural Tropism
In addition to its flexibility, LNP8002 exhibits inherent passive targeting to the liver, driven by the natural biodistribution behavior of its optimized lipid composition. Upon intravenous administration, the nanoparticles preferentially accumulate in hepatic tissue, ensuring high transfection efficiency in hepatocytes without the need for active targeting ligands. This built-in liver tropism makes LNP8002 particularly valuable for metabolic disease models, hepatic gene therapy, and protein expression studies, where precise and efficient RNA delivery to the liver is critical.
Flexible Administration for Multi-Organ Targeting
LNP8002 is uniquely adaptable to different routes of administration, providing researchers with full control over biodistribution and experimental outcomes:
Intravenous (IV) Injection: Delivers strong expression in the liver and spleen, leveraging both passive liver targeting and optimized circulation properties — ideal for hepatic RNA therapy or systemic applications:
Intramuscular (IM) Injection: Produces concentrated expression at the injection site, liver, and spleen, closely mirroring the distribution of approved mRNA vaccines, making it ideal for vaccine and protein expression research.
Intraperitoneal (IP) Injection: Enables multi-organ RNA delivery to the liver, spleen, lungs, kidneys, and gastrointestinal tract for systemic applications requiring broad biodistribution.
This flexibility allows LNP8002 to adapt seamlessly to a wide spectrum of experimental and therapeutic objectives.
Enhanced Safety and Biocompatibility
Formulated with biodegradable lipids and free from organic solvents such as ethanol, LNP8002 minimizes injection site irritation and systemic toxicity. Its optimized particle size and surface charge ensure effective endosomal escape and controlled RNA release while preserving tissue integrity. The result is a highly safe, low-immunogenic, and biocompatible platform suitable for repeated dosing and long-term studies.
Accelerating Translational RNA Research
By combining efficiency, safety, passive liver targeting, and multi-route flexibility, the SatredaLNP™ 8002 kit redefines systemic RNA delivery. Whether used for vaccine development, gene therapy, or multi-organ transfection, this technology provides a fast, reliable, and scalable solution that bridges the gap between fundamental research and clinical translation — propelling RNA therapeutics into a new era of precision and accessibility.
Intraperitoneal injection (IP) of 6 μg Fluc mRNA per mouse. IVIS imaging and tissue distribution analysis were performed 6 hours post-administration.
Intramuscular injection (IM): Fluc mRNA at a dose of 10 μg per mouse. IVIS imaging and tissue distribution were performed 6 hours after administration.
Intravenous injection (IV): 6 μg of Fluc mRNA per mouse. IVIS imaging was performed 6 hours after administration.
Luc mRNA-SatredaLNP compound (Hand mixing)
Luc mRNA-SatredaLNP (Microfluidic devices)